Combined medicine for treating acute T lymphocytic leukemia and combined central nervous system leukemia and application thereof
The invention provides a combined medicine for treating acute T lymphocytic leukemia and combined central nervous system leukemia and application of the combined medicine. The combined medicine for treating T-ALL comprises dasatinib and dasatinib. According to the invention, the drug dasatinib and the drug dasatinib are creatively combined to be used as the drug for treating T-ALL, so that a remarkable synergistic interaction effect is exerted, and compared with a single drug, the drug has the effects of remarkably inhibiting T-ALL cell proliferation, prolonging the survival time of a T-ALL mouse model and relieving the progress of T-ALL combined with leukemia of a central nervous system. The invention provides a new strategy and thought for treating acute T lymphocytic leukemia and acute T lymphocytic leukemia combined with central nervous system leukemia, and has very remarkable significance..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 05. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
CHEN JUNZHU [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-05, Last update posted on www.tib.eu: 2024-03-18, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
CN117338786 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000881163 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000881163 | ||
| 003 | DE-627 | ||
| 005 | 20240322140419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000881163 | ||
| 035 | |a (EPA)CN117338786 | ||
| 035 | |a (EPA)89356927 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a CHEN JUNZHU |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combined medicine for treating acute T lymphocytic leukemia and combined central nervous system leukemia and application thereof |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-05, Last update posted on www.tib.eu: 2024-03-18, Last updated: 2024-03-22 | ||
| 520 | |a The invention provides a combined medicine for treating acute T lymphocytic leukemia and combined central nervous system leukemia and application of the combined medicine. The combined medicine for treating T-ALL comprises dasatinib and dasatinib. According to the invention, the drug dasatinib and the drug dasatinib are creatively combined to be used as the drug for treating T-ALL, so that a remarkable synergistic interaction effect is exerted, and compared with a single drug, the drug has the effects of remarkably inhibiting T-ALL cell proliferation, prolonging the survival time of a T-ALL mouse model and relieving the progress of T-ALL combined with leukemia of a central nervous system. The invention provides a new strategy and thought for treating acute T lymphocytic leukemia and acute T lymphocytic leukemia combined with central nervous system leukemia, and has very remarkable significance. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a TANG YANLAI |4 aut | |
| 700 | 0 | |a LUO XUEQUN |4 aut | |
| 700 | 0 | |a HUANG LIBIN |4 aut | |
| 700 | 0 | |a KE ZHIYONG |4 aut | |
| 700 | 0 | |a ZHAO GUANGYIN |4 aut | |
| 700 | 0 | |a ZHANG XIAOLI |4 aut | |
| 700 | 0 | |a LI YU |4 aut | |
| 700 | 0 | |a WANG LINA |4 aut | |
| 700 | 0 | |a LIANG CONG |4 aut | |
| 700 | 0 | |a LUO JIESI |4 aut | |
| 700 | 0 | |a FAN ZHONG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 05. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89356927/publication/CN117338786A1?q=CN117338786 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 01 | ||